Back to Search
Start Over
Efficacy of lenalidomide in high‐risk diffuse large B‐cell lymphoma.
- Source :
- British Journal of Haematology; Feb2020, Vol. 188 Issue 4, pe33-e36, 4p, 1 Chart, 1 Graph
- Publication Year :
- 2020
-
Abstract
- Historical outcomes remain poor for patients with relapsed/refractory diffuse large B-cell (DLBCL) and high-grade B-cell lymphoma (HGBCL) (Crump I et al i ., [3]). We included patients treated from 2011 to 2018, including those with transformed disease, patients with I MYC i , I BCL2 i and I BCL6 i translocations (including HGBCL), and patients treated with concurrent rituximab. Though more patients with transformed FL were treated with concurrent rituximab compared to patients with I de novo i GCB disease, there was no difference in efficacy between patients treated with or without concurrent rituximab. One patient with "triple HIT" disease had a complete response, which allowed the patient to receive chimeric antigen receptor T-cell therapy. [Extracted from the article]
- Subjects :
- DIFFUSE large B-cell lymphomas
MANTLE cell lymphoma
Subjects
Details
- Language :
- English
- ISSN :
- 00071048
- Volume :
- 188
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- British Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 141659587
- Full Text :
- https://doi.org/10.1111/bjh.16302